In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI
The paradigm of mast cells in type 2 diabetes is changing. Although they were first considered deleterious inflammatory cells, now they seem to be important players driving adipose tissue homeostasis. Here we have employed a flow cytometry-based approach for measuring the surface expression of 4 pro...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2022.818388/full |
| _version_ | 1819158881772765184 |
|---|---|
| author | David Lopez-Perez David Lopez-Perez Anaïs Redruello-Romero Jesús Garcia-Rubio Carlos Arana Luis A. Garcia-Escudero Francisco Tamayo Javier Salmeron Julio Galvez Julio Galvez Julio Galvez Josefa Leon Josefa Leon Ángel Carazo Ángel Carazo |
| author_facet | David Lopez-Perez David Lopez-Perez Anaïs Redruello-Romero Jesús Garcia-Rubio Carlos Arana Luis A. Garcia-Escudero Francisco Tamayo Javier Salmeron Julio Galvez Julio Galvez Julio Galvez Josefa Leon Josefa Leon Ángel Carazo Ángel Carazo |
| author_sort | David Lopez-Perez |
| collection | DOAJ |
| description | The paradigm of mast cells in type 2 diabetes is changing. Although they were first considered deleterious inflammatory cells, now they seem to be important players driving adipose tissue homeostasis. Here we have employed a flow cytometry-based approach for measuring the surface expression of 4 proteins (CD45, CD117, CD203c, and FcϵRI) on mast cells of omental (o-WAT) and subcutaneous white adipose tissue (s-WAT) in a cohort of 96 patients with morbid obesity. The cohort was split into three groups: non-T2D, pre-T2D, and T2D. Noteworthy, patients with T2D have a mild condition (HbA1c <7%). In o-WAT, mast cells of patients with T2D have a decrease in the surface expression of CD45 (p=0.0013), CD117 (p=0.0066), CD203c (p=0.0025), and FcϵRI (p=0.043). Besides, in s-WAT, the decrease was seen only in CD117 (p=0.046). These results indicate that T2D affects more to mast cells in o-WAT than in s-WAT. The decrease in these four proteins has serious effects on mast cell function. CD117 is critical for mast cell survival, while CD45 and FcϵRI are important for mast cell activation. Additionally, CD203c is only present on the cell surface after granule release. Taking together these observations, we suggest that mast cells in o-WAT of patients with T2D have a decreased survival, activation capacity, and secretory function. |
| first_indexed | 2024-12-22T16:31:42Z |
| format | Article |
| id | doaj.art-678e58d92c574fe5bcbf06c120c9bb5c |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-12-22T16:31:42Z |
| publishDate | 2022-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-678e58d92c574fe5bcbf06c120c9bb5c2022-12-21T18:20:03ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922022-03-011310.3389/fendo.2022.818388818388In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRIDavid Lopez-Perez0David Lopez-Perez1Anaïs Redruello-Romero2Jesús Garcia-Rubio3Carlos Arana4Luis A. Garcia-Escudero5Francisco Tamayo6Javier Salmeron7Julio Galvez8Julio Galvez9Julio Galvez10Josefa Leon11Josefa Leon12Ángel Carazo13Ángel Carazo14Department of Pharmacology, Faculty of Pharmacy, University of Granada, Granada, SpainResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, SpainResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, SpainSurgery Unit, San Cecilio University Hospital, Granada, SpainEndocrinology and nutrition department, Virgen de la Luz University Hospital, Cuenca, SpainDepartment of Statistics and Operative Research, Faculty of Sciences, University of Valladolid, Valladolid, SpainSurgery Unit, San Cecilio University Hospital, Granada, SpainGastroenterology Unit, San Cecilio University Hospital, Granada, SpainDepartment of Pharmacology, Faculty of Pharmacy, University of Granada, Granada, SpainResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, SpainCentro de Investigación Biomédica En Red para Enfermedades Hepáticas y Digestivas (CIBER-EHD), Center for Biomedical Research, University of Granada, Granada, SpainResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, SpainClinical Management Unit of Digestive Disease, San Cecilio University Hospital, Granada, SpainResearch Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, SpainClinical Management Unit of Digestive Disease, San Cecilio University Hospital, Granada, SpainThe paradigm of mast cells in type 2 diabetes is changing. Although they were first considered deleterious inflammatory cells, now they seem to be important players driving adipose tissue homeostasis. Here we have employed a flow cytometry-based approach for measuring the surface expression of 4 proteins (CD45, CD117, CD203c, and FcϵRI) on mast cells of omental (o-WAT) and subcutaneous white adipose tissue (s-WAT) in a cohort of 96 patients with morbid obesity. The cohort was split into three groups: non-T2D, pre-T2D, and T2D. Noteworthy, patients with T2D have a mild condition (HbA1c <7%). In o-WAT, mast cells of patients with T2D have a decrease in the surface expression of CD45 (p=0.0013), CD117 (p=0.0066), CD203c (p=0.0025), and FcϵRI (p=0.043). Besides, in s-WAT, the decrease was seen only in CD117 (p=0.046). These results indicate that T2D affects more to mast cells in o-WAT than in s-WAT. The decrease in these four proteins has serious effects on mast cell function. CD117 is critical for mast cell survival, while CD45 and FcϵRI are important for mast cell activation. Additionally, CD203c is only present on the cell surface after granule release. Taking together these observations, we suggest that mast cells in o-WAT of patients with T2D have a decreased survival, activation capacity, and secretory function.https://www.frontiersin.org/articles/10.3389/fendo.2022.818388/fullmast celladipose tissueobesitytype 2 diabetesflow cytometrybariatric surgery |
| spellingShingle | David Lopez-Perez David Lopez-Perez Anaïs Redruello-Romero Jesús Garcia-Rubio Carlos Arana Luis A. Garcia-Escudero Francisco Tamayo Javier Salmeron Julio Galvez Julio Galvez Julio Galvez Josefa Leon Josefa Leon Ángel Carazo Ángel Carazo In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI Frontiers in Endocrinology mast cell adipose tissue obesity type 2 diabetes flow cytometry bariatric surgery |
| title | In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI |
| title_full | In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI |
| title_fullStr | In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI |
| title_full_unstemmed | In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI |
| title_short | In Obese Patients With Type 2 Diabetes, Mast Cells in Omental Adipose Tissue Decrease the Surface Expression of CD45, CD117, CD203c, and FcϵRI |
| title_sort | in obese patients with type 2 diabetes mast cells in omental adipose tissue decrease the surface expression of cd45 cd117 cd203c and fcϵri |
| topic | mast cell adipose tissue obesity type 2 diabetes flow cytometry bariatric surgery |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2022.818388/full |
| work_keys_str_mv | AT davidlopezperez inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT davidlopezperez inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT anaisredruelloromero inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT jesusgarciarubio inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT carlosarana inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT luisagarciaescudero inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT franciscotamayo inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT javiersalmeron inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT juliogalvez inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT juliogalvez inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT juliogalvez inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT josefaleon inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT josefaleon inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT angelcarazo inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri AT angelcarazo inobesepatientswithtype2diabetesmastcellsinomentaladiposetissuedecreasethesurfaceexpressionofcd45cd117cd203candfceri |